HC Wainwright Upgrades Edgewise Therapeutics to Strong Buy

Analysts see multiple near-term catalysts for the biotech company's pipeline

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Edgewise Therapeutics (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on rare diseases, was upgraded to a "strong-buy" rating by analysts at HC Wainwright. The firm also issued earnings estimates for Edgewise Therapeutics through 2026, projecting continued operating losses as the company advances its clinical trials.

Why it matters

The upgrade and analyst projections suggest that Edgewise's pipeline of experimental therapies, including treatments for kidney disorders and neuromuscular diseases, are progressing well and could provide significant upside for the company if upcoming data readouts are positive. However, the near-term financial outlook indicates the company will likely need additional funding before reaching profitability.

The details

In their research note, HC Wainwright analysts cited several upcoming clinical catalysts that could drive the stock higher, including 12-week data for Edgewise's lead candidate EDG-7500 in hypertrophic cardiomyopathy and Phase 1 results for EDG-15400 in heart failure, both expected in the first half of 2026. The analysts also pointed to pivotal data for the company's Becker muscular dystrophy drug sevasemten, anticipated in Q4 2026.

  • The 12-week data for EDG-7500 in hypertrophic cardiomyopathy is expected in the first half of 2026.
  • The Phase 1 results for EDG-15400 in heart failure are expected in the first half of 2026.
  • The pivotal data for sevasemten in Becker muscular dystrophy is anticipated in Q4 2026.

The players

Edgewise Therapeutics

A clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases.

HC Wainwright

An investment banking firm that provides research coverage and analysis on Edgewise Therapeutics.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Edgewise Therapeutics' pipeline of experimental therapies for rare diseases appears to be progressing well, with several key data readouts expected in the next few years. However, the company will likely need additional funding before reaching profitability, as it continues to invest in advancing its clinical trials.